NEW ATAI-Logo_Primary.png
atai Life Sciences erhöht seine Beteiligung an COMPASS Pathways
01 déc. 2021 10h17 HE | Atai Life Sciences
Dies zeigt atais Vertrauen in die Phase-2b-Daten von COMPASS und dessen Potenzial für Patienten mit therapieresistenter Depression Bestätigt, dass COMPASS den breit gefächerten Innovationsansatz von...
NEW ATAI-Logo_Primary.png
atai Life Sciences Increases its Ownership Position in COMPASS Pathways
29 nov. 2021 07h00 HE | atai Life Sciences
Demonstrates atai’s confidence in COMPASS’ Phase 2b data and its potential for patients with treatment-resistant depression Reinforces COMPASS as highly complementary to atai’s diversified approach...
NEW ATAI-Logo_Primary.png
atai Life Sciences legt Finanzergebnisse für das dritte Quartal 2021 und Unternehmens-Update vor
17 nov. 2021 05h48 HE | Atai Life Sciences
- Positive Topline-Ergebnisse aus der Phase-2b-Studie von COMP360 - - Topline-Daten der RL-007-Phase-2a-Studie zu kognitiver Beeinträchtigung in Verbindung mit Schizophrenie werden Ende des vierten...
NEW ATAI-Logo_Primary.png
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
15 nov. 2021 06h59 HE | atai Life Sciences
-Positive topline results from COMP360’s Phase 2b study- -RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4- -Continued progress across 11...
NEW ATAI-Logo_Primary.png
atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update
08 nov. 2021 08h30 HE | atai Life Sciences
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
NEW ATAI-Logo_Primary.png
atai Life Sciences to Participate in Upcoming November Investor Conferences
05 nov. 2021 16h30 HE | atai Life Sciences
NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
NEW ATAI-Logo_Primary.png
atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort of Phase 2a Trial for Novel Treatment of Cognitive Impairment Associated with Schizophrenia
01 nov. 2021 09h00 HE | atai Life Sciences
NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai") today announced that it has observed encouraging interim data from the first 8-patient cohort of its Phase 2a...
NEW ATAI-Logo_Primary.png
atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change
19 oct. 2021 07h00 HE | atai Life Sciences
NEW YORK and BERLIN, Oct. 19, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company, today announced the launch of its new philanthropic...
NEW ATAI-Logo_Primary.png
atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)
11 oct. 2021 08h00 HE | atai Life Sciences
NEW YORK, Oct. 11, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
NEW ATAI-Logo_Primary.png
DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder
21 sept. 2021 08h00 HE | atai Life Sciences
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid use...